DIABETES INSULIN PUMP SUPPLY STORE BUSINESS PLAN

I. Executive Summary

Company Description

PulsePath Health—named to reflect continuous, trusted delivery of vital insulin pump supplies—operates in the U.S. medical e-commerce sector as a direct-to-consumer provider of essential diabetes management supplies launching 2026. We sell insulin pump reservoirs, infusion sets, adhesives, backup batteries, and temperature-stable consumables through a specialized online platform tailored to the insulin pump community. We manage wholesale procurement, inventory in a temperature-controlled facility, fulfillment, and last-mile delivery to ensure medical-grade handling and rapid restock. One clear point: we deliver critical, climate-controlled supplies reliably to pump users’ doors.

What sets us apart is integrated end-to-end cold-chain operations, pump-community UX features, and subscription-managed replenishment that target adult and pediatric insulin pump users and their caregivers in the U.S., plus specialty clinics and diabetes educators. Short-term goals: launch December 2026, reach 5,000 active subscribers and 60% gross margin in year one. Long-term goals: scale to 75,000 subscribers by year five, expand clinic partnerships, and sustain >70% retention through superior service and inventory reliability. One clear point: we scale logistics and retention to turn recurring medical needs into predictable revenue.

Problem

Managing supplies for insulin pumps imposes continuous logistical work and mental load on patients and caregivers. Families must track infusion sets and sensors, coordinate multiple vendors and insurance rules, and time orders to avoid gaps—creating anxiety, last-minute purchases, and occasional therapy interruptions.

Current distribution is fragmented and unreliable for end users. Existing channels leave users juggling paperwork, variable delivery windows, and non-medical storage, which increases risk of shortages. There is a clear need for a U.S. direct-to-consumer, medical-grade, temperature-controlled supply chain that delivers consistently. One line: a dependable, direct-to-door solution eliminates life-critical supply anxiety.

Solution

Managing insulin-pump supplies creates a high logistical and mental burden for patients and caregivers who juggle manual orders from multiple sources and face the risk of running out of infusion sets, CGM sensors, and reservoirs. Our service solves this by providing a streamlined e-commerce platform that automates recurring orders, centralizes supplies, and guarantees tracked door-to-door delivery to ensure uninterrupted insulin-pump therapy.

Key features include recurring order automation, age-friendly navigation, logistics integration for tracked shipments, and scheduled supply management to remove manual reordering and reduce supply risk.

Mission Statement

Our mission is to simplify life for the insulin pump community by providing unparalleled convenience and reliability. We eliminate supply-management stress through innovative technology and superior logistics so customers never face a shortage of critical supplies. We aim to be the most trusted partner in daily diabetes management across the United States, empowering customers to focus on their lives, not logistics.

Key Success Factors

Achieving these measurable targets is critical to deliver the projected financial and operational outcomes.

• 85% repeat customer rate by 2030 to sustain lifetime value and margin.
• CAC starting at $45, falling to $35 to keep marketing efficient and payback short.
• Breakeven within 3 months of launch to validate unit economics and conserve cash.
• Scale revenue from $823,000 to $24.8M in five years to demonstrate market traction and investor returns.
• Strong manufacturer relationships to ensure continuous supply of high-demand medical devices.

Financial Summary

Financial snapshot for the Executive Summary: strong unit economics, rapid payback, and high investor returns.

Financial requirements: minimum cash on hand $853,000 (Feb-26) to cover launch and operations; breakeven expected Mar-26 (3 months); payback on initial investments 10 months. Anticipated return: project IRR 22.7% and ROE 36.85%.

Outlook: profitable from launch with scalable margins and a clear path to 10% COGS by 2030.

Funding Requirements

We seek USD 853,000 to fund Capex, marketing, first-year payroll, a temperature‑controlled warehouse deposit plus initial inventory, delivering a project IRR of 22.7%, ROE of 36.85%, Year 1 revenue of USD 823,000 with EBITDA USD 237,000, Year 5 revenue USD 24,872,000 with EBITDA USD 19,743,000, a 10‑month payback on initial investments, and a target COGS of 10% of revenue by 2030.